Mersana Days Sales Outstanding vs Free Cash Flow Yield Analysis

MRSN Stock

USD 2.21 0.31 12.30%

Mersana Therapeutics financial indicator trend analysis is infinitely more than just investigating Mersana Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mersana Therapeutics is a good investment. Please check the relationship between Mersana Therapeutics Days Sales Outstanding and its Free Cash Flow Yield accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.

Days Sales Outstanding vs Free Cash Flow Yield

Days Sales Outstanding vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mersana Therapeutics Days Sales Outstanding account and Free Cash Flow Yield. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Mersana Therapeutics' Days Sales Outstanding and Free Cash Flow Yield is -0.43. Overlapping area represents the amount of variation of Days Sales Outstanding that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Mersana Therapeutics, assuming nothing else is changed. The correlation between historical values of Mersana Therapeutics' Days Sales Outstanding and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Sales Outstanding of Mersana Therapeutics are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Days Sales Outstanding i.e., Mersana Therapeutics' Days Sales Outstanding and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-0.43

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Days Sales Outstanding

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Mersana Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mersana Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.As of the 16th of November 2024, Selling General Administrative is likely to grow to about 62.5 M, while Issuance Of Capital Stock is likely to drop about 118.6 M.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	855K	927K	1.5M	1.1M
Interest Income	65K	2.9M	11.0M	11.6M

Depreciation And Amortization Interest Income

Mersana Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Property Plant And Equipment Gross
Total Assets		0.9	0.79	0.82	0.57	0.85	0.93	0.33	-0.96	-0.79	0.81	0.97	0.9	0.09	0.47	1.0	0.54	0.91	0.78	0.41	0.89	0.58	0.84	0.64	-0.45	0.88
Other Current Liab	0.9		0.88	0.65	0.58	0.7	0.91	0.39	-0.85	-0.81	0.91	0.88	0.84	0.13	0.19	0.88	0.69	0.86	0.78	0.44	0.85	0.73	0.84	0.7	-0.49	0.93
Total Current Liabilities	0.79	0.88		0.47	0.63	0.52	0.71	0.77	-0.72	-0.76	0.87	0.74	0.74	0.38	0.04	0.77	0.61	0.72	0.69	0.43	0.74	0.53	0.74	0.74	-0.47	0.75
Total Stockholder Equity	0.82	0.65	0.47		0.15	0.98	0.8	0.0	-0.78	-0.52	0.71	0.78	0.87	0.27	0.75	0.83	0.19	0.84	0.56	-0.15	0.77	0.53	0.65	0.09	-0.29	0.67
Other Liab	0.57	0.58	0.63	0.15		0.25	0.48	0.48	-0.53	-0.86	0.36	0.52	0.4	-0.31	-0.21	0.56	0.43	0.47	0.82	0.72	0.67	0.17	0.77	0.8	-0.28	0.57
Net Tangible Assets	0.85	0.7	0.52	0.98	0.25		0.87	0.04	-0.79	-0.63	0.73	0.81	0.91	0.24	0.7	0.87	0.15	0.92	0.66	-0.06	0.85	0.6	0.74	0.17	-0.34	0.77
Property Plant And Equipment Net	0.93	0.91	0.71	0.8	0.48	0.87		0.14	-0.91	-0.8	0.84	0.94	0.88	0.1	0.47	0.93	0.43	0.94	0.82	0.33	0.91	0.77	0.87	0.54	-0.56	0.97
Current Deferred Revenue	0.33	0.39	0.77	0.0	0.48	0.04	0.14		-0.27	-0.39	0.44	0.26	0.31	0.48	-0.22	0.32	0.34	0.22	0.27	0.34	0.27	0.04	0.31	0.58	-0.2	0.2
Net Debt	-0.96	-0.85	-0.72	-0.78	-0.53	-0.79	-0.91	-0.27		0.74	-0.78	-0.99	-0.8	-0.13	-0.57	-0.96	-0.52	-0.83	-0.77	-0.42	-0.84	-0.53	-0.82	-0.62	0.61	-0.84
Retained Earnings	-0.79	-0.81	-0.76	-0.52	-0.86	-0.63	-0.8	-0.39	0.74		-0.71	-0.75	-0.71	0.03	-0.09	-0.78	-0.36	-0.81	-0.99	-0.48	-0.94	-0.55	-0.98	-0.68	0.51	-0.86
Accounts Payable	0.81	0.91	0.87	0.71	0.36	0.73	0.84	0.44	-0.78	-0.71		0.8	0.83	0.48	0.3	0.79	0.5	0.83	0.69	0.12	0.81	0.74	0.77	0.46	-0.6	0.81
Cash	0.97	0.88	0.74	0.78	0.52	0.81	0.94	0.26	-0.99	-0.75	0.8		0.82	0.12	0.54	0.97	0.53	0.87	0.77	0.44	0.85	0.59	0.83	0.64	-0.61	0.89
Non Current Assets Total	0.9	0.84	0.74	0.87	0.4	0.91	0.88	0.31	-0.8	-0.71	0.83	0.82		0.26	0.44	0.9	0.33	0.89	0.69	0.12	0.87	0.73	0.77	0.4	-0.25	0.83
Non Currrent Assets Other	0.09	0.13	0.38	0.27	-0.31	0.24	0.1	0.48	-0.13	0.03	0.48	0.12	0.26		0.33	0.1	-0.17	0.19	-0.05	-0.49	0.11	0.22	0.05	-0.2	-0.35	0.03
Other Assets	0.47	0.19	0.04	0.75	-0.21	0.7	0.47	-0.22	-0.57	-0.09	0.3	0.54	0.44	0.33		0.5	-0.1	0.46	0.18	-0.3	0.35	0.13	0.26	-0.2	-0.29	0.27
Cash And Short Term Investments	1.0	0.88	0.77	0.83	0.56	0.87	0.93	0.32	-0.96	-0.78	0.79	0.97	0.9	0.1	0.5		0.49	0.92	0.79	0.4	0.89	0.56	0.84	0.62	-0.47	0.87
Net Receivables	0.54	0.69	0.61	0.19	0.43	0.15	0.43	0.34	-0.52	-0.36	0.5	0.53	0.33	-0.17	-0.1	0.49		0.33	0.32	0.59	0.29	0.21	0.34	0.69	-0.17	0.47
Common Stock Total Equity	0.91	0.86	0.72	0.84	0.47	0.92	0.94	0.22	-0.83	-0.81	0.83	0.87	0.89	0.19	0.46	0.92	0.33		0.81	0.21	0.92	0.65	0.87	0.46	-0.5	0.92
Common Stock Shares Outstanding	0.78	0.78	0.69	0.56	0.82	0.66	0.82	0.27	-0.77	-0.99	0.69	0.77	0.69	-0.05	0.18	0.79	0.32	0.81		0.44	0.95	0.53	0.99	0.62	-0.57	0.85
Non Current Liabilities Total	0.41	0.44	0.43	-0.15	0.72	-0.06	0.33	0.34	-0.42	-0.48	0.12	0.44	0.12	-0.49	-0.3	0.4	0.59	0.21	0.44		0.27	0.1	0.38	0.93	-0.27	0.45
Capital Surpluse	0.89	0.85	0.74	0.77	0.67	0.85	0.91	0.27	-0.84	-0.94	0.81	0.85	0.87	0.11	0.35	0.89	0.29	0.92	0.95	0.27		0.66	0.98	0.51	-0.52	0.9
Other Current Assets	0.58	0.73	0.53	0.53	0.17	0.6	0.77	0.04	-0.53	-0.55	0.74	0.59	0.73	0.22	0.13	0.56	0.21	0.65	0.53	0.1	0.66		0.59	0.3	-0.37	0.79
Other Stockholder Equity	0.84	0.84	0.74	0.65	0.77	0.74	0.87	0.31	-0.82	-0.98	0.77	0.83	0.77	0.05	0.26	0.84	0.34	0.87	0.99	0.38	0.98	0.59		0.6	-0.58	0.89
Total Liab	0.64	0.7	0.74	0.09	0.8	0.17	0.54	0.58	-0.62	-0.68	0.46	0.64	0.4	-0.2	-0.2	0.62	0.69	0.46	0.62	0.93	0.51	0.3	0.6		-0.4	0.65
Deferred Long Term Liab	-0.45	-0.49	-0.47	-0.29	-0.28	-0.34	-0.56	-0.2	0.61	0.51	-0.6	-0.61	-0.25	-0.35	-0.29	-0.47	-0.17	-0.5	-0.57	-0.27	-0.52	-0.37	-0.58	-0.4		-0.53
Property Plant And Equipment Gross	0.88	0.93	0.75	0.67	0.57	0.77	0.97	0.2	-0.84	-0.86	0.81	0.89	0.83	0.03	0.27	0.87	0.47	0.92	0.85	0.45	0.9	0.79	0.89	0.65	-0.53

Click cells to compare fundamentals

Mersana Therapeutics Account Relationship Matchups

Mersana Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	107.5M	273.4M	206.1M	334.3M	226.1M	180.4M
Other Current Liab	9.1M	16.2M	29.0M	44.2M	22.7M	17.9M
Total Current Liabilities	24.1M	30.0M	47.5M	91.5M	63.6M	48.5M
Total Stockholder Equity	78.3M	228.1M	121.7M	92.1M	36.9M	65.7M
Other Liab	28.8M	282K	525K	117.0M	134.6M	141.3M
Net Tangible Assets	78.3M	228.1M	155.5M	92.1M	105.9M	73.5M
Property Plant And Equipment Net	4.8M	12.7M	14.9M	14.5M	11.5M	8.2M
Current Deferred Revenue	4.8M	4.0M	3.9M	30.6M	28.1M	20.7M
Net Debt	(54.6M)	(238.5M)	(139.8M)	(244.4M)	(140.7M)	(147.8M)
Retained Earnings	(192.4M)	(280.4M)	(450.5M)	(654.7M)	(826.4M)	(785.0M)
Accounts Payable	7.3M	8.3M	12.3M	14.0M	7.3M	8.2M
Cash	62.4M	255.1M	177.9M	280.7M	174.6M	140.4M
Non Current Assets Total	6.2M	14.8M	17.2M	15.1M	12.0M	11.2M
Non Currrent Assets Other	1.1M	2.2M	1.9M	183K	478K	454.1K
Other Assets	1.5M	13.1M	2.4M	661K	760.2K	722.1K
Cash And Short Term Investments	99.8M	255.1M	177.9M	280.7M	209.1M	161.3M
Common Stock Shares Outstanding	43.5M	61.5M	70.6M	93.7M	116.1M	121.9M
Liabilities And Stockholders Equity	107.5M	273.4M	206.1M	334.3M	226.1M	180.4M
Non Current Liabilities Total	5.2M	15.3M	36.8M	150.8M	125.5M	66.2M
Capital Surpluse	173.0M	270.7M	508.5M	572.2M	658.0M	690.9M
Other Current Assets	1.5M	3.5M	21.9M	8.5M	5.0M	5.8M
Other Stockholder Equity	270.7M	508.5M	572.2M	746.9M	863.2M	906.4M
Total Liab	29.2M	45.3M	84.4M	242.3M	189.2M	114.7M
Property Plant And Equipment Gross	4.8M	12.7M	22.5M	22.2M	20.6M	11.2M
Total Current Assets	101.3M	258.6M	188.9M	319.2M	214.1M	169.2M
Accumulated Other Comprehensive Income	(8K)	25K	0.0	(152K)	11K	11.6K
Property Plant Equipment	4.8M	1.7M	14.9M	14.5M	16.6M	17.5M
Retained Earnings Total Equity	(164.2M)	(192.4M)	(280.4M)	(450.5M)	(405.4M)	(385.2M)
Short Term Investments	10.5M	37.4M	0.0	151.8M	34.5M	50.7M
Net Invested Capital	83.2M	233.1M	146.4M	117.0M	62.1M	113.2M
Net Working Capital	77.3M	228.6M	141.4M	227.7M	150.4M	143.9M

Pair Trading with Mersana Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Mersana Stock

0.61

DMAC

DiaMedica Therapeutics

Pair Corr

Moving against Mersana Stock

0.87	VALN	Valneva SE ADR	Pair Corr
0.57	VCNX	Vaccinex	Pair Corr
0.53	ME	23Andme Holding	Pair Corr
0.53	DTIL	Precision BioSciences	Pair Corr
0.49	DRMA	Dermata Therapeutics	Pair Corr

The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.

The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Mersana Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mersana Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mersana Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mersana Therapeutics Stock:

How To Invest In Mersana

Details

Is Mersana Stock a good investment?

Details

What is Mersana Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.

You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.85)

Revenue Per Share

0.247

Quarterly Revenue Growth

(0.79)

Return On Assets

(0.26)

Return On Equity

(2.13)

The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Mersana Days Sales Outstanding vs Free Cash Flow Yield Analysis

Days Sales Outstanding vs Free Cash Flow Yield

Days Sales Outstanding vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Days Sales Outstanding

Free Cash Flow Yield

Mersana Therapeutics fundamental ratios Correlations

Mersana Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Mersana Therapeutics fundamental ratios Accounts

Pair Trading with Mersana Therapeutics

Moving together with Mersana Stock

Moving against Mersana Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Net Tangible Assets	+ 0.98	Total Stockholder Equity
Other Stockholder Equity	+ 0.98	Capital Surpluse
Cash	+ 0.97	Total Assets
Property Plant And Equipment Gross	+ 0.97	Property Plant And Equipment Net

Common Stock Shares Outstanding	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Other Stockholder Equity	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.96	Net Debt
Net Debt	- 0.96	Total Assets
Capital Surpluse	- 0.94	Retained Earnings